Challenges in the Choice of Nonstatin Medications for Low‐Density Lipoprotein‐C Lowering for Cardiovascular Risk Reduction
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.125.044134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Merle Myerson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Myerson Medical and Health Writing & Editing Cooperstown NY USA. Hauptthemen laut MEDLINE: Cholesterol, LDL, Cardiovascular Diseases, Anticholesteremic Agents, Dyslipidemias. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Atherosclerotic cardiovascular diseases continue to be a leading cause of death globally. Although statin medications remain the cornerstone of treatment for lowering low‐density lipoprotein cholesterol and reducing cardiovascular risk, there is a proportion of patients in whom treatment with statins may not achieve the guideline recommended low‐density lipoprotein cholesterol targets despite using maximally tolerated doses, or for various reasons, patients are unable or unwilling to intensify or continue statins. In these instances, use of nonstatin medications like ezetimibe, bempedoic acid, or PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors (alirocumab, evolocumab, inclisiran) in addition to maximally tolerated statin therapy can lead to additional lowering of low‐density lipoprotein cholesterol and beneficial reductions in cardiovascular events. This review provides an overview of the evidence supporting the use of nonstatin low‐density lipoprotein cholesterol lowering medications for cardiovascular risk reduction and practical considerations for the use of these agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Myerson Medical and Health Writing & Editing Cooperstown NY USA.
- General Cardiology Clinic Knight Cardiovascular Institute, Oregon Health & Science University Portland OR USA.
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Department of Family Medicine, School of Medicine University of Colorado Anschutz Medical Campus Aurora CO USA.
- Hellenic Endocrine Network Athens Greece.
- Endocrinology, Diabetes and Metabolism Clinics Patras Greece.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine Loyola University Chicago IL USA.
ORCID-Profile: Merle Myerson, Bruce A Warden, Joseph J Saseen, Rodis Paparodis
Zitieren
APA
Myerson, M., Warden, B. A., Saseen, J. J., & Paparodis, R. (2025). Challenges in the Choice of Nonstatin Medications for Low‐Density Lipoprotein‐C Lowering for Cardiovascular Risk Reduction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.044134
Vancouver
Myerson M, Warden BA, Saseen JJ, Paparodis R. Challenges in the Choice of Nonstatin Medications for Low‐Density Lipoprotein‐C Lowering for Cardiovascular Risk Reduction. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.044134
BibTeX
@article{Myerson2025,
author = {Myerson, Merle and Warden, Bruce A and Saseen, Joseph J and Paparodis, Rodis},
title = {Challenges in the Choice of Nonstatin Medications for Low‐Density Lipoprotein‐C Lowering for Cardiovascular Risk Reduction},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.125.044134}
}
EUVIMED